1
|
Silva MC, Fernandes Â, Oliveira M, Resende C, Correia A, de-Freitas-Junior JC, Lavelle A, Andrade-da-Costa J, Leander M, Xavier-Ferreira H, Bessa J, Pereira C, Henrique RM, Carneiro F, Dinis-Ribeiro M, Marcos-Pinto R, Lima M, Lepenies B, Sokol H, Machado JC, Vilanova M, Pinho SS. Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. Cancer Immunol Res 2020; 8:1407-1425. [PMID: 32933968 DOI: 10.1158/2326-6066.cir-20-0264] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 07/03/2020] [Accepted: 09/08/2020] [Indexed: 11/16/2022]
Abstract
Tumor growth is accompanied with dramatic changes in the cellular glycome, such as the aberrant expression of complex branched N-glycans. However, the role of this protumoral N-glycan in immune evasion and whether its removal contributes to enhancement of immune recognition and to unleashing an antitumor immune response remain elusive. We demonstrated that branched N-glycans are used by colorectal cancer cells to escape immune recognition, instructing the creation of immunosuppressive networks through inhibition of IFNγ. The removal of this "glycan-mask" exposed immunogenic mannose glycans that potentiated immune recognition by DC-SIGN-expressing immune cells, resulting in an effective antitumor immune response. We revealed a glycoimmune checkpoint in colorectal cancer, highlighting the therapeutic efficacy of its deglycosylation to potentiate immune recognition and, thus, improving cancer immunotherapy.
Collapse
Affiliation(s)
- Mariana C Silva
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Ângela Fernandes
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal
| | - Maria Oliveira
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal
| | - Carlos Resende
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal
| | - Alexandra Correia
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Julio C de-Freitas-Junior
- Cellular and Molecular Oncobiology Program, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Aonghus Lavelle
- Sorbonne Université, INSERM, Saint-Antoine Research Center (CRSA), Paris, France
| | - Jéssica Andrade-da-Costa
- Cellular and Molecular Oncobiology Program, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Magdalena Leander
- Department of Hematology, Hospital Center of Porto, Porto, Portugal.,Multidisciplinary Unit for Biomedical Research, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Helena Xavier-Ferreira
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - José Bessa
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal
| | - Carina Pereira
- CINTESIS - Centre for Health Technology and Services Research, University of Porto, Porto, Portugal.,Molecular Oncology and Viral Pathology Group, IPO Porto Research Group (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
| | - Rui M Henrique
- Department of Pathology and Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.,Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Fátima Carneiro
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Department of Pathology, Hospital Center of São João, Porto, Portugal.,Faculty of Medicine, University of Porto, Porto, Portugal
| | - Mário Dinis-Ribeiro
- CINTESIS - Centre for Health Technology and Services Research, University of Porto, Porto, Portugal.,Department of Gastroenterology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
| | - Ricardo Marcos-Pinto
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.,Department of Gastroenterology, Hospital Center of Porto, Porto, Portugal.,Medical Faculty, Centre for Research in Health Technologies and Information Systems, Porto, Portugal
| | - Margarida Lima
- Department of Hematology, Hospital Center of Porto, Porto, Portugal.,Multidisciplinary Unit for Biomedical Research, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Bernd Lepenies
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.,Immunology Unit and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany
| | - Harry Sokol
- Sorbonne Université, INSERM, Saint-Antoine Research Center (CRSA), Paris, France.,INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.,Department of Gastroenterology, Saint Antoine Hospital, Assistance Publique - Hopitaux de Paris, Sorbonne Universités, Paris, France
| | - José C Machado
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Faculty of Medicine, University of Porto, Porto, Portugal
| | - Manuel Vilanova
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.,Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
| | - Salomé S Pinho
- Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal. .,Faculty of Medicine, University of Porto, Porto, Portugal
| |
Collapse
|
2
|
de Souza WF, Fortunato-Miranda N, Robbs BK, de Araujo WM, de-Freitas-Junior JC, Bastos LG, Viola JPB, Morgado-Díaz JA. Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One 2013; 8:e74994. [PMID: 24069372 PMCID: PMC3777902 DOI: 10.1371/journal.pone.0074994] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2013] [Accepted: 08/09/2013] [Indexed: 12/19/2022] Open
Abstract
The altered expressions of claudin proteins have been reported during the tumorigenesis of colorectal cancer. However, the molecular mechanisms that regulate these events in this cancer type are poorly understood. Here, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells. This increase was related to increased cell migration and the formation of anchorage-dependent and anchorage-independent colonies. We further showed that the ERK1/2 and PI3K-Akt pathways were involved in the regulation of these effects because specific pharmacological inhibition blocked these events. Genetic manipulation of claudin-1 and claudin-3 in HT-29 cells showed that the overexpression of claudin-1 resulted in decreased cell migration; however, migration was not altered in cells that overexpressed claudin-3. Furthermore, the overexpression of claudin-3, but not that of claudin-1, increased the tight junction-related paracellular flux of macromolecules. Additionally, an increased formation of anchorage-dependent and anchorage-independent colonies were observed in cells that overexpressed claudin-3, while no such changes were observed when claudin-1 was overexpressed. Finally, claudin-3 silencing alone despite induce increase proliferation, and the formation of anchoragedependent and -independent colonies, it was able to prevent the EGF-induced increased malignant potential. In conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.
Collapse
Affiliation(s)
- Waldemir F. de Souza
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Natalia Fortunato-Miranda
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Bruno K. Robbs
- Grupo de Regulação Gênica, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Wallace M. de Araujo
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Julio C. de-Freitas-Junior
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Lilian G. Bastos
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - João P. B. Viola
- Grupo de Regulação Gênica, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - José A. Morgado-Díaz
- Grupo de Biologia Estrutural, Programa de Biologia Celular, Centro de Pesquisas, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|